Skip to search formSkip to main contentSkip to account menu

RC 3095

Known as: RC-3095 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
OBJECTIVE To evaluate the antiinflammatory effects of RC-3095 in 2 experimental models of arthritis, collagen-induced arthritis… 
Highly Cited
1994
Highly Cited
1994
Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with… 
Highly Cited
1994
Highly Cited
1994
In this study, we investigated the effect of bombesin/GRP antagonist RC-3095 on the growth of CFPAC-1 human pancreatic cancer… 
Highly Cited
1994
Highly Cited
1994
Specific receptors for bombesin/gastrin releasing peptide (GRP) on the androgen‐independent human prostate cancer cell lines PC‐3… 
Highly Cited
1993
Highly Cited
1993
Nude mice bearing xenografts of the androgen‐independent human prostate‐cancer cell line PC‐3 were treated for 4 weeks with… 
Highly Cited
1992
Highly Cited
1992
Recently, it was reported that bombesin/gastrin-releasing peptide (GRP) have mitogenic effects on some human breast cancer cell… 
Highly Cited
1992
Highly Cited
1992
The effects of treatment with a bombesin receptor antagonist [D‐Tpi6, Leu13Ψ(CH2NH) Leu14]BN(6–14)(RC‐3095) and the combination… 
Highly Cited
1992
Highly Cited
1992
BACKGROUND Many breast cancers are estrogen independent, and even in patients who initially respond to estrogen suppression… 
Highly Cited
1991
Highly Cited
1991
Nude mice bearing xenografts of HT-29 human colon cancer cell line were treated for 4 weeks with a [D-Trp6] agonist of… 
Highly Cited
1991
Highly Cited
1991
Female Syrian golden hamsters with N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancers were treated for 2 months with new…